---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-013889"
form_type: "8-K"
ticker: "DWTX"
cik: "0001818844"
company_name: "Dogwood Therapeutics, Inc."
filed_at: "2024-10-30T23:59:59+00:00"
generated_at: "2026-05-30T08:27:52.857426+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Dogwood Therapeutics regains Nasdaq compliance; phase 2a Long-COVID data expected mid-Nov

## Summary
- Regained Nasdaq minimum bid price compliance; closing bid price >= $1.00 for 10 consecutive trading days.
- Top-line results from phase 2a study of IMC-2 for Long-COVID expected mid-November 2024.
- Integration of Pharmagesic (Holdings) Inc. acquisition (closed early Oct 2024) ongoing.

## SEC filing metadata
- accession: 0001558370-24-013889
- form_type: 8-K
- ticker: DWTX
- cik: 0001818844
- company_name: Dogwood Therapeutics, Inc.
- filed_at: 2024-10-30T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1818844/000155837024013889/0001558370-24-013889-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1818844/000155837024013889/viri-20241029x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-013889
- JSON: https://secwatch.observer/filing/0001558370-24-013889.json
- Plain text: https://secwatch.observer/filing/0001558370-24-013889.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.